Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21681 | 0.92 | — | — | |
| SCHEMBL2582328 | 0.92 | CA1 (0.47) | CA1CA2CA7CA13 | |
| Methane SCHEMBL27881065 | 0.88 | — | — | |
| SCHEMBL16760664 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL5733160 | 0.88 | — | — | |
| SCHEMBL4178096 | 0.88 | — | — | |
| Lithium SCHEMBL31511739 | 0.88 | — | — | |
| SCHEMBL10486665 | 0.81 | CA1 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL1146027 | 0.74 | CA2 (0.39) | CA1CA2CA7CA13 | |
| SCHEMBL10756128 | 0.74 | CA1 (0.33) | CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211873-A1 | Synthesis of cyproterone acetate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-21 | — | — | US | claimed |
| EP-1501858-A2 | FURTHER SYNTHESES OF CYPROTERONE ACETATE | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2005-02-02 | — | — | EP | claimed |
| US-20040024230-A1 | Synthesis of cyproterone acetate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| WO-2003092578-A2 | FURTHER SYNTHESES OF CYPROTERONE ACETATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-11-13 | — | — | WO | claimed |
| US-20060211873-A1 | Synthesis of cyproterone acetate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-21 | — | — | US | disclosed |
| EP-1501858-A2 | FURTHER SYNTHESES OF CYPROTERONE ACETATE | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2005-02-02 | — | — | EP | disclosed |
| US-20040024230-A1 | Synthesis of cyproterone acetate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| WO-2003092578-A2 | FURTHER SYNTHESES OF CYPROTERONE ACETATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-11-13 | — | — | WO | disclosed |
| EP-1359154-A1 | Further syntheses of cyproterone acetate | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024230-A1 | Synthesis of cyproterone acetate | CYP17A1, CYP19A1, CYP21A2 | CA1 1770/4885CA2 3066/4885CA7 913/4885 |
| US-20060211873-A1 | Synthesis of cyproterone acetate | CYP17A1, CYP19A1, HSD17B7 | CA1 1809/4885CA2 2963/4885CA7 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.